Biomira chronicles
Weekly stock price for Biomira (TSX:BRA; BIOM) on the Toronto exchange tracked against selected events since 2000. A. 6/29/00 - BRA reacquires rights to Theratope breast cancer vaccine from Chiron, which obtained co-development and co-marketing rights in May 1997
B. 3/30/01 - Terminates a co-development deal for its idiotypic vaccine against B cell lymphoma after partner Biovector decides to focus on its own drug delivery systemsC. 5/3/01 - Grants Merck KGaA (FSE:MRK) rights to Theratope and L-BLP25 (Stimuvax) liposomal vaccine for non-small cell lung cancer (NSCLC)D. 10/1/01 - Raises $15M in a private placementE. 11/28/01 - Suspends development of two cancer programs: a Phase I autologous vaccine and its liposomal interleukin-2 (L-IL-2), which was in Phase II testing. Says it will lay off 22 of its 185 employees and out-license the programs to focus on its Theratope and BLP25 vaccines.F. 9/19/02 - Falls 41% to $1.35 on NASDAQ after an interim review showed Theratope did not meet either primary endpoint, survival or time to disease progression, in a Phase III trial to treat metastatic breast cancerG. 6/11/03 - Gains $1.03 (37%) to $3.83 on NASDAQ after announcing that it would present full Phase III data for Theratope in JuneH. 6/17/03 - Falls 63% to $1.49 on NASDAQ after data confirmed that Theratope did not meet the primary endpoints in the Phase III trialI. 10/1/03 - Raises $16.3M in a private placement...